You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 26, 2024

Claims for Patent: 8,524,731


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 8,524,731
Title:Use of opioid antagonists to attenuate endothelial cell proliferation and migration
Abstract: The invention provides methods of attenuating, e.g., inhibiting or reducing, cellular proliferation and migration, particularly endothelial cell proliferation and migration, including that associated with angiogenesis, using opioid antagonists, including, but not limited to, those that are peripherally restricted antagonists.
Inventor(s): Moss; Jonathan (Chicago, IL), Lingen; Mark (Oak Park, IL), Singleton; Patrick A. (Chicago, IL), Garcia; Joe G. N. (Chicago, IL), Yuan; Chun-Su (Chicago, IL)
Assignee: The University of Chicago (Chicago, IL)
Application Number:11/379,010
Patent Claims:1. A method of treatment of a disorder characterized by VEGF-induced hyperproliferation of endothelial cells, comprising administering to a subject in need thereof an effective amount of methylnaltrexone and an antiangiogenic agent which is bevacizumab, wherein the disorder is cancer.

2. The method of claim 1, wherein the cells are cancer cells.

3. The method of claim 1, wherein the methylnaltrexone is administered simultaneously or sequentially with the antiangiogenic agent.

4. The method of claim 1, wherein the cells are vascular endothelial cells.

5. The method of claim 4, wherein the hyperproliferation of vascular endothelial cells is associated with angiogenesis.

6. The method of claim 1, wherein the subject is taking concurrent opioid therapy.

7. The method of claim 1, wherein the subject is not taking concurrent opioid therapy.

8. The method of claim 1, wherein the subject is taking concurrent chronic opioid therapy.

9. The method of claim 1, wherein the subject is not taking concurrent chronic opioid therapy.

10. The method of claim 1, wherein the effective amount of methylnaltrexone is such that the subject has effective circulating blood plasma levels of methylnaltrexone continuously for at least 1 week.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.